Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis

Show full item record



Permalink

http://hdl.handle.net/10138/304066

Citation

Robin , M , Chevret , S , Koster , L , Wolschke , C , Yakoub-Agha , I , Bourhis , J H , Chevallier , P , Cornelissen , J J , Remenyi , P , Maertens , J , Poire , X , Craddock , C , Socie , G , Itälä-Remes , M , Schouten , H C , Marchand , T , Passweg , J , Blaise , D , Damaj , G , Ozkurt , Z N , Zuckerman , T , Cluzeau , T , Labussiere-Wallet , H , Cammenga , J , McLornan , D , Chalandon , Y & Kroger , N 2019 , ' Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis ' , Haematologica , vol. 104 , no. 6 , pp. 1230-1236 . https://doi.org/10.3324/haematol.2018.201400

Title: Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
Author: Robin, Marie; Chevret, Sylvie; Koster, Linda; Wolschke, Christine; Yakoub-Agha, Ibrahim; Bourhis, Jean Henri; Chevallier, Patrice; Cornelissen, Jan J.; Remenyi, Peter; Maertens, Johan; Poire, Xavier; Craddock, Charles; Socie, Gerard; Itälä-Remes, Maija; Schouten, Harry C.; Marchand, Tony; Passweg, Jakob; Blaise, Didier; Damaj, Gandhi; Ozkurt, Zubeyde Nur; Zuckerman, Tsila; Cluzeau, Thomas; Labussiere-Wallet, Helene; Cammenga, Jörg; McLornan, Donal; Chalandon, Yves; Kroger, Nicolaus
Contributor: University of Helsinki, Clinicum
Date: 2019-05-31
Language: eng
Number of pages: 7
Belongs to series: Haematologica
ISSN: 0390-6078
URI: http://hdl.handle.net/10138/304066
Abstract: The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft-versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis (n= 287). The cumulative incidences of grade II-IV acute graft-versus-host disease among patients who were or were not given antihuman T-lymphocyte immunoglobulin were 26% and 41%, respectively. The corresponding incidences of chronic graft-versus-host disease were 52% and 55%, respectively. Non-adjusted overall survival, disease-free survival and non-relapse mortality rates were 55% versus 53%, 49% versus 45%, and 32% versus 31%, respectively, among the patients who were or were not given antihuman T-lymphocyte immunoglobulin. An adjusted model confirmed that the risk of acute graft-versus-host disease was lower following antihuman T-lymphocyte immunoglobulin (hazard ratio, 0.54; P= 0.010) while it did not decrease the risk of chronic graft-versus-host disease. The hazard ratios for overall survival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not influence disease-free survival, graft-versus-host disease, relapse-free survival or relapse risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this study demonstrates that antihuman T-lymphocyte immunoglobulin decreases the risk of acute graft-versushost disease without increasing the risk of relapse.
Subject: STEM-CELL TRANSPLANTATION
VERSUS-HOST-DISEASE
AGNOGENIC MYELOID METAPLASIA
PROGNOSTIC SCORING SYSTEM
UNRELATED DONORS
GRUPPO-ITALIANO
MIDOLLO-OSSEO
POLYCYTHEMIA-VERA
SOCIETE FRANCAISE
WORKING GROUP
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1230.full.pdf 584.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record